P
Peter M. Kern
Publications - 2
Citations - 2727
Peter M. Kern is an academic researcher. The author has contributed to research in topics: Hypereosinophilic syndrome & Septic shock. The author has an hindex of 1, co-authored 2 publications receiving 2606 citations.
Papers
More filters
Journal ArticleDOI
Intensive insulin therapy and pentastarch resuscitation in severe sepsis.
Frank M. Brunkhorst,Christoph Engel,Frank Bloos,Andreas Meier-Hellmann,Max Ragaller,Norbert Weiler,Onnen Moerer,Matthias Gruendling,Michael Oppert,Stefan Grond,Derk Olthoff,Ulrich Jaschinski,Stefan John,Rolf Rossaint,Tobias Welte,Martin Schaefer,Peter M. Kern,Evelyn Kuhnt,Michael Kiehntopf,Christiane S. Hartog,Charles Natanson,Markus Loeffler,Konrad Reinhart +22 more
TL;DR: The use of intensive insulin therapy placed critically ill patients with sepsis at increased risk for serious adverse events related to hypoglycemia and HES was harmful, and its toxicity increased with accumulating doses.
Journal ArticleDOI
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
Gerald J. Gleich,Florence Roufosse,Geoffrey Chupp,Stanislas Faguer,Bastian Walz,Andreas Reiter,Steven W. Yancey,Jane H Bentley,Jonathan Steinfeld,Gabriel Ricardo García,Pablo Pascale,Luis Wehbe,Daniel Engelbert Blockmans,Martti Anton Antila,Daniela Cavalet Blanco,Andreia Luisa Francisco Pez,Jean-Emmanuel Kahn,Guillaume Lefèvre,Antoine Néel,Peter M. Kern,Andreas Reiter,Tobias Welte,Fabrizio Pane,Alessandro M. Vannucchi,Ruth Cerino-Javier,Dante D. Hernández-Colín,Héctor Glenn Valdéz-López,Izabela R. Kupryś-Lipińska,Jacek Musial,Eniko Mihaly,Viola Maria Popov,Vladimir Ivanov,Nikolay Tsyba,Maria C. Cid,Maria Laura Fox,Guillermo Sanz Santillana,Andrew J. Wardlaw,Praveen Akuthota,Joseph H. Butterfield,Geoffrey L. Chupp,Devi Jhaveri,Marc E. Rothenberg +41 more
TL;DR: A double-blind, placebo-controlled, phase III study as mentioned in this paper showed that mepolizumab reduces disease flares for patients with uncontrolled FIP1-like-1-platelet-derived growth factor receptor α-negative hypereosinophilic syndrome (HES) and two or more flares in the previous year.